|
 |
Cutaneous T-Cell LymphomaThis page contains recent news articles, when available, and an overview of Cutaneous T-Cell Lymphoma but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Background information on Cutaneous T-Cell Lymphoma
FOXBusiness...multi-center study of PDX with vitamin B12 and folic acid supplementation in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). BioCryst Reports Fourth Quarter and Year End 2007 Financial ... - Mar 4, 2008 CNNMoney.com (press release)Forodesine HCl pivotal trial in patients with cutaneous t-cell lymphoma In October, BioCryst began enrolling patients in a pivotal, multinational trial of Cyclacel's David Glover to Present at New York Academy of Sciences ... - Mar 4, 2008 FOXBusiness...modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly and cutaneous T-cell lymphoma (CTCL). BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal ... - Feb 28, 2008 Earthtimes,...that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its CuraGen and TopoTarget Report Belinostat Results Presented at ASH ... - Dec 10, 2007 CNNMoney.comIn a poster entitled, "Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma: Results of a Phase II Study," CuraGen and TopoTarget Report Belinostat Results Presented at ASH ... - Dec 10, 2007 PR Newswire (press release),..."Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma: Results of a Phase II Study," updated data on a BioCryst Provides Forodesine HCl Update - Dec 6, 2007 CNNMoney.comDr. Duvic's presentation entitled, "Response to Oral Forodesine in Refractory Cutaneous T-Cell Lymphoma: Interim Results of a Phase I/II Study" will provide Birmingham's BioCryst drops testing of experimental cancer drug in ... - Dec 7, 2007 The Birmingham News - al.com,Trials will continue on the drug's oral capsules for the treatment of a different cancer, refractory cutaneous T-cell lymphoma, BioCryst said. BioCryst Pharma to Halt IV Drug Study - Dec 6, 2007 Houston Chronicle,...in the treatment of patients with refractory cutaneous T-cell lymphoma at the annual meeting of the American Society of Hematology in Atlanta on Sunday. Cyclacel Reports Updated Phase I Sapacitabine Data at 2007 ASH Meeting - Dec 16, 2007 PR-USA.net (press release),A Phase II study of sapacitabine in patients with advanced cutaneous T cell lymphoma is currently ongoing. Sapacitabine is part of a deep pipeline of small BioCryst Says Forodesine HCl As A Single Agent Or In Combination ... - Dec 14, 2007 Trading Markets (press release),...anti-cancer compound, forodesine HCl, exhibited clinical activity as a single oral agent in patients with advanced refractory cutaneous T-cell lymphoma. Gloucester's cancer drug found effective against lymphoma - Dec 11, 2007 Pharmaceutical Business ReviewBy Staff Writer Of the 73 evaluable cutaneous T-cell lymphoma (CTCL) patients, an overall response rate of 37% (27/73) was reported, with four complete Novartis to sell 4 new cancer drugs by 2011 -WSJ - Dec 4, 2007 Reuters...also aims to launch ASA404 for non-small-cell lung cancer, SOM230 for a rare group of neroendocrine tumours and LBH589 for cutaneous T-cell lymphoma. Favrille to Report New Data on FavId (Now Specifid) at American ... - Dec 6, 2007 CNNMoney.com...and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma. BioCryst's forodesine HCI shows positive results in Phase I/II trial - Dec 14, 2007 CNNMoney.com...forodesine HCI demonstrated clinical activity as a single oral agent in patients with advanced refractory cutaneous T-cell lymphoma,' the company said. Novartis aims to bring 4 new cancer drugs to market by 2011 ... - Dec 5, 2007 CNNMoney.com...aims to launch by 2011 are ASA404 for non-small-cell lung cancer, SOM230 for rare neuroendocrine tumours and LBH589 for cutaneous T-cell lymphoma. Gloucester Pharmaceuticals Announces Positive Interim Results of ... - Dec 10, 2007 Business Wire (press release),Gloucester is conducting pivotal phase II studies of romidepsin for patients with cutaneous T-cell lymphoma (CTCL) and for patients with peripheral T-cell Cyclacel Pharmaceuticals Provides Year End 2007 Pipeline Update ... - Dec 4, 2007 PR-USA.net (press release),Sapacitabine (CYC682), an orally-available, cell cycle modulating nucleoside analog, is in Phase II for the treatment of cutaneous T-cell lymphoma (CTCL) Novartis Makes Plans to Release Four New Cancer Drugs by 2011 - Dec 4, 2007 Wall Street Journal...to launch by 2011 are ASA404 for non-small cell lung cancer; SOM230 for a rare group of neuroendocrine tumors and LBH589 for cutaneous T-cell lymphoma. Data Presented at 2007 ASH Meeting Demonstrate Activity of ... - Dec 14, 2007 CNNMoney.com...interim data from the Phase I/II clinical study of oral forodesine HCl in the treatment of subjects with refractory cutaneous T-cell lymphoma (CTCL). Marketing Application for Vorinostat Filed in Europe for the ... - Dec 4, 2007 PR-USA.net (press release),...the European Medicines Agency (EMEA) for vorinostat for the treatment of advanced, refractory cutaneous T-cell lymphoma (CTCL) in the European Union. NCI renewal grant to develop new cancer therapies - Dec 4, 2007 EurekAlert (press release),Recently, histone deacetylase inhibitors have been approved for the treatment of patients with cutaneous T cell lymphoma, a type of cancer of the immune Radnor pharmaceutical company gets $14.5M in funding - Nov 27, 2007 Phoenix Business Journal (subscription),The company's lead drug is Clearazidea, a topical agent for cutaneous T-cell lymphoma. Clearazidea is currently in late-stage testing. Gloucester Pharmaceuticals Announces Presentation Of Romidepsin ... - Dec 3, 2007 Medical News Today (press release),The Company is conducting a pivotal phase II study of romidepsin for patients with cutaneous T-cell lymphoma (CTCL) and has initiated a pivotal phase II Merck seeks European vorinostat approval - Nov 27, 2007 Checkbiotech.org (press release),The company asked the European Medicines Agency to approve the drug as a treatment for advanced, refractory cutaneous T-cell lymphoma. Amended: Novartis Expects To Commence Sales Of Four New Cancer ... - Dec 5, 2007 RTT News,...and LBH589, are for the treatment of non-small-cell lung cancer, a rare group of neuroendocrine tumors, and cutaneous T-cell lymphoma, respectively. Yaupon Therapeutics Closes $14.5 Million Financing - Nov 28, 2007 American Venture Magazine (press release),...a topically delivered cytotoxic agent for the treatment of cutaneous T-cell lymphoma (CTCL) that is currently in pivotal clinical studies. Merck Seeks European Vorinostat Approval - 26 Nov 2007 Houston Chronicle,The company asked the European Medicines Agency to approve the drug as a treatment for advanced, refractory cutaneous T-cell lymphoma. Valley funders join $14.5M round for Yaupon - 26 Nov 2007 Bizjournals.com,The financing will support the ongoing clinical development program for a topically delivered cytotoxic agent for the treatment of cutaneous T-cell lymphoma. Cyclacel Pharmaceuticals Provides Year End 2007 Pipeline Update ... - 26 Nov 2007 Business Wire (press release),Sapacitabine (CYC682), an orally-available, cell cycle modulating nucleoside analog, is in Phase II for the treatment of cutaneous T-cell lymphoma (CTCL) James River Coal Updates Sales Contract Position; Issues FY08 ... - 26 Nov 2007 RTT News,Additionally, the company added that the Phase II study of Sapacitabine as a treatment for patients with cutaneous T-cell lymphoma or CTCL would be expanded curagen and topotarget Announce Presentations on Belinostat at the ... - 26 Nov 2007 PR Newswire (press release),The presentation details are as follows: Title: Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma: allergies? no, conquering something much more serious - Nov 18, 2007 Inland Valley Daily Bulletin,...outcomes and treatment considerations. cutaneous t-cell lymphoma, accounts for about two percent of all cases of non-hodgkin's lymphoma and mostly allos therapeutics reports third quarter 2007 financial results - Nov 5, 2007 CNNMoney.com...multi-center study of pdx with vitamin b12 and folic acid supplementation in patients with relapsed or refractory cutaneous t-cell lymphoma (ctcl). up genmab to present zanolimumab and ofatumumab data at ash - Nov 9, 2007 PR Newswire UK (press release),...summary: genmab will present phase ii non-cutaneous t-cell lymphoma zanolimumab data and pre-clinical ofatumumab data on at the 2007 annual meeting of the favrille announces $21.1 million registered direct offering - Nov 2, 2007 CNNMoney.com...including a second product candidate, fav-201, for the treatment of cutaneous t-cell lymphoma. to receive additional information on the company, biocryst reports third quarter 2007 financial results and ... - Nov 8, 2007 CNNMoney.com...biocryst enrolled the first patient in a pivotal phase ii clinical trial of oral forodesine hcl in patients with cutaneous t- cell lymphoma (ctcl). the cyclacel pharmaceuticals to present at the lazard capital markets ... - Nov 14, 2007 American Digital Networks (press release),...is in phase ii for the treatment of cutaneous t-cell lymphoma (ctcl) and in phase i in patients with hematologic malignancies. seliciclib (cyc202), cyclacel pharmaceuticals reports third quarter 2007 financial ... - Nov 7, 2007 Business Wire (press release),...in patients with advanced cutaneous t-cell lymphoma (ctcl). the primary objective of the study is to evaluate the tolerability and response rate of Genmab says its new HuMax-CD4 drug has unique action to treat cancer - Oct 15, 2007 Forbes,...a potential cancer treatment currently being developed to treat cutaneous T-cell lymphoma and non-cutaneous T-cell lymphoma, has 'unique mechanisms of Danish shares close lower, led down by Torm, AP Moller; Norden ... - Oct 15, 2007 CNNMoney.comThe group said its HuMax-CD4 (zanolimumab), a potential cancer treatment currently being developed to treat cutaneous T-cell lymphoma and non-cutaneous Favrille to Host Conference Call and Live Webcast to Discuss Third ... - Oct 16, 2007 CNNMoney.com...and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma. Genmab Shares Rise After Trial Amended, Bank Resumes Coverage - Oct 11, 2007 BloombergGenmab said today that Australian authorities had granted orphan drug status for HuMax-CD4's use to treat refractory cutaneous T-cell lymphoma, BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL ... - Oct 12, 2007 CNNMoney.com...enrollment of the pivotal trial of its lead oncology drug candidate, forodesine HCL, in the treatment of patients with cutaneous T-cell lymphoma (CTCL). BioCryst Starts Cancer Study Enrollment - Oct 12, 2007 CNNMoney.comThe international trial will involve patients with cutaneous T-Cell lymphoma, a rare form of cancer affecting the skin. The trial is being conducted under a CuraGen Announces Top-Line Phase II Results on Velafermin - Oct 11, 2007 CNNMoney.com2007 in Atlanta, GA: Belinostat Title: Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma: Results of Genmab Amends HuMax-CD4 Pivotal Study in CTCL - Oct 12, 2007 PipelineReview.com (press release),...today it has amended the design of the ongoing pivotal study of HuMax-CD4® (zanolimumab) to treat refractory cutaneous T-cell lymphoma (CTCL) patients. New cancer drugs could help in autoimmune disease - Oct 7, 2007 Scientific AmericanZolinza is approved in the United States to treat cutaneous T cell lymphoma, a type of skin cancer. Hancock said SAHA appears to bolster the work of Favrille to Present at BIO InvestorForum - Oct 2, 2007 CNNMoney.com...and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma. Cyclacel Pharmaceuticals Acquires Specialty Pharmaceutical ... - Oct 8, 2007 PharmaLive.com (press release),Sapacitabine (CYC682), an orally-available, cell cycle modulating nucleoside analog, is in Phase II for the treatment of cutaneous T-cell lymphoma (CTCL) Business brief - Oct 13, 2007 The Birmingham News - al.com,BioCryst Pharmaceuticals Inc. said Friday it has started enrolling cutaneous T-cell lymphoma patients in a pivotal trial of oral doses of its experimental CuraGen Corporation Announces Appointment of Dr. Timothy M ... - Sep 19, 2007 CNNMoney.com...belinostat monotherapy for the treatment of cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lymphoma (PTCL) in the fourth quarter of 2007. Favrille: The Wall Street Analyst Forum Presentation Transcript - Sep 20, 2007 Seeking Alpha,...the treatment of cutaneous T-Cell lymphoma and recently acquired lymphoma and recently acquired a series of optimized anti-CD20 monoclonal antibodies. Childhood friends Lira and Hernandez give cancer the boot - Sep 27, 2007 Eagle Tribune,...recall whether he was four or five when he was diagnosed with a rare form of cancer, at least for someone of his age, called cutaneous T-cell lymphoma. Cyclacel Pharmaceuticals CEO Speaks About His Company - Sep 25, 2007 Seeking Alpha,...be further Phase I data in patients with hematological cancers or cancers of the blood and Phase II data in a cancer called cutaneous T-cell lymphoma. Peramivir Stumbles In Phase II Influenza Study; BioCryst Falls - Sep 20, 2007 BioWorld Online,...based BioCryst also has a late-stage cancer drug, Fodosine, which is in Phase III testing in cutaneous T-cell lymphoma. Fodosine is partnered with Cambridge BioCryst Pharmaceuticals down after disappointing flu trial - Sep 20, 2007 SmallCapInvestorAccording to Chow, BioCryst could initiate a trial for Fodosine cutaneous T-cell lymphoma during the third quarter of 2007. In the fourth quarter, Allos Therapeutics Initiates Study of PDX in Patients with ... - Aug 15, 2007 CNNMoney.com..."Therapies currently used to treat cutaneous T-cell lymphoma fail to produce durable remissions in the majority of patients with advanced disease. Favrille CEO to Present at Bear Stearns Healthcare Conference - Sep 4, 2007 CNNMoney.com...and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma. Allos Therapeutics Initiates Study Of PDX In Patients With ... - Aug 15, 2007 RTT News,...novel antifolate PDX or pralatrexate with vitamin B12 and folic acid supplementation in patients with relapsed or refractory cutaneous T-cell lymphoma. Allos Therapeutics Begins Patient Enrollment In Phase 1 Study Of ... - Aug 15, 2007 RTT News,The company said patients with either relapsed or refractory cutaneous T- cell lymphoma will receive PDX as part of a weekly schedule for two or three weeks Genmab gains milestone and antibody - Aug 14, 2007 BiopharmaReporter.com,This antibody is being developed to treat non-cutaneous T-cell lymphoma and cutaneous T-cell lymphoma. "HuMax-CD4 is a nice fit with the rest of Genmab's Genmab Announces 2007 First Half Year Results - Aug 22, 2007 BourSonews,...rights to HuMax-CD4(R) (zanolimumab) from Merck Serono SA and announced final data from the HuMax-CD4 Phase II data in cutaneous T-cell lymphoma (CTCL). Cutaneous T-cell Lymphoma On The Rise, Research Shows - Jul 17, 2007 Science Daily (press release)Science Daily — Cutaneous T-cell lymphoma, a rare and mysterious cancer, is on the rise, according to the first nationwide study of the disease in a decade. Genmab reports positive phase 2 data for cancer drug candidate ... - Jul 2, 2007 Forbes,AS announced positive results from two phase 2 trials for its drug candidate Humax-CD4 in treatment of the cancer form CTCL (Cutaneous T Cell Lymphoma). NCCN Updates Non-Hodgkin's Lymphoma Guidelines - Jun 20, 2007 Genetic Engineering News (press release),The Panel also added new guidelines for Mycosis Fungoides/Sezary Syndrome (otherwise known as Cutaneous T-Cell Lymphoma (CTCL)), a disease in which certain Genmab 'Celebrating' Return Of Worldwide HuMax-CD4 Rights - Jul 1, 2007 BioWorld Online,By Jennifer Boggs Genmab A/S said it is moving full steam ahead with its late-stage HuMax-CD4 compound in cutaneous T-cell lymphoma after regaining full Favrille Announces Data From Phase 2 Clinical Trial of FavId for ... - Jun 11, 2007 Earthtimes.org...and proprietary cost- effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma. CuraGen "market outperform" - Jun 15, 2007 newratings.com...clinical updates on PXD101 were extremely promising, exhibiting significant response rates in patients with advanced cutaneous T-cell lymphoma (CTCL). Search the web for more resources on Cutaneous T-Cell Lymphoma |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2006 MONGABAY.COM |